198 related articles for article (PubMed ID: 27919895)
1. Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.
López-Diaz MD; Culebras E; Rodríguez-Avial I; Rios E; Viñuela-Prieto JM; Picazo JJ; Rodríguez-Avial C
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919895
[TBL] [Abstract][Full Text] [Related]
2. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487
[TBL] [Abstract][Full Text] [Related]
3. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla
Johnston BD; Thuras P; Porter SB; Clabots C; Johnson JR
Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2069-2075. PubMed ID: 33893571
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.
Castanheira M; Davis AP; Serio AW; Krause KM; Mendes RE
Diagn Microbiol Infect Dis; 2019 May; 94(1):73-77. PubMed ID: 30661726
[TBL] [Abstract][Full Text] [Related]
6. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.
Cox G; Ejim L; Stogios PJ; Koteva K; Bordeleau E; Evdokimova E; Sieron AO; Savchenko A; Serio AW; Krause KM; Wright GD
ACS Infect Dis; 2018 Jun; 4(6):980-987. PubMed ID: 29634241
[TBL] [Abstract][Full Text] [Related]
7. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
[TBL] [Abstract][Full Text] [Related]
8. The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia.
Alyamani EJ; Khiyami AM; Booq RY; Majrashi MA; Bahwerth FS; Rechkina E
Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):1. PubMed ID: 28061852
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.
López Díaz MC; Ríos E; Rodríguez-Avial I; Simaluiza RJ; Picazo JJ; Culebras E
Int J Antimicrob Agents; 2017 Aug; 50(2):191-196. PubMed ID: 28577932
[TBL] [Abstract][Full Text] [Related]
10. Genetic basis of enzymatic resistance of E. coli to aminoglycosides.
Ojdana D; Sieńko A; Sacha P; Majewski P; Wieczorek P; Wieczorek A; Tryniszewska E
Adv Med Sci; 2018 Mar; 63(1):9-13. PubMed ID: 28763677
[TBL] [Abstract][Full Text] [Related]
11. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.
Cha MK; Kang CI; Kim SH; Cho SY; Ha YE; Wi YM; Chung DR; Peck KR; Song JH;
Antimicrob Agents Chemother; 2015 Sep; 59(9):5834-7. PubMed ID: 26124174
[TBL] [Abstract][Full Text] [Related]
14. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
[TBL] [Abstract][Full Text] [Related]
16. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.
Livermore DM; Mushtaq S; Warner M; Zhang JC; Maharjan S; Doumith M; Woodford N
J Antimicrob Chemother; 2011 Jan; 66(1):48-53. PubMed ID: 21078604
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
[TBL] [Abstract][Full Text] [Related]
18. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
Bilinskaya A; Linder KE; Kuti JL
Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli.
İnce G; Mirza HC; Üsküdar Güçlü A; Gümüş H; Erol Ç; Başustaoğlu A
J Antimicrob Chemother; 2021 Nov; 76(12):3192-3196. PubMed ID: 34499728
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
